Atea Pharmaceuticals Inc

AVIRNASDAQ · USD
3.99USD0.00 (+0.76%)
139

Atea Pharmaceuticals Inc (AVIR) Covered Calls

Atea Pharmaceuticals Inc trades in the Biotechnology industry with an IV Rank of 28.97%, low versus the past year. AVIR's highest covered call setup is the $7.50 strike expiring Dec 17, 2027, sorted by theoretical annualized return. It's 82.04% out of the money with 396 days to expiration, a 83.25% return until expiration, and a 76.74% theoretical annualized return. Across the setups shown, annualized returns run from 21.92% to 76.74% at strikes between $5.00 and $7.50, with 151 to 396 days to expiration, as of Nov 16, 2026.

Read more

Running AVIR covered calls helps you generate income from Atea Pharmaceuticals Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AVIR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AVIR stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AVIR covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AVIR covered call is worth writing.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.

2027-12-173967.5082.040.051.90343.0083.2576.74-1.21+0.49301.85
2027-04-161515.0021.360.351.05123.0029.8572.16-8.50+0.5020.70
2027-12-173965.0021.360.103.2098.0023.7921.92-2.43+0.681813.10

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank28.97% Low
  • Market cap (M$)320
  • 52 weeks high-38.14%
  • 52 weeks low36.64%
  • Analyst recommendationBuy
    1.67
  • Target price$9.00
    125.56% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-09
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.96
  • EPS growth next 5 years12.27%

As of Nov 18, 2026